Renal & Urinary

Diabetic nephropathy: screening and management

Clinical Overview and When to Suspect Diabetic Nephropathy

— Leading cause of ESKD in the US (~45% of incident cases on dialysis registries).

— Develops in ~30–40% of T1DM and ~20–40% of T2DM patients over decades.

— Higher incidence in Black, Hispanic, Native American, and Asian-American populations.

— Stage 1: Hyperfiltration (↑GFR) at diagnosis.

— Stage 2: Silent glomerular damage, normoalbuminuria, 2–5 yr.

— Stage 3: Moderately increased albuminuria (30–300 mg/g), 5–15 yr.

— Stage 4: Severely increased albuminuria (>300 mg/g), declining GFR.

— Stage 5: ESKD, typically 15–25 yr after onset.

— Long-standing DM (>5 yr T1DM; any duration T2DM since onset often unknown).

— Concurrent diabetic retinopathy — strong corroborating evidence in T1DM.

— Slowly progressive proteinuria without hematuria or active sediment.

— Hypertension that worsens in parallel with albuminuria.

— Hematuria with RBC casts, rapid GFR decline (>5 mL/min/yr), nephrotic syndrome <5 yr after T1DM onset, absence of retinopathy in T1DM, systemic symptoms.

— These should prompt nephrology referral and consideration of biopsy.

Board pearl: In a T1DM patient with proteinuria but no retinopathy, suspect a non-diabetic cause of CKD — retinopathy and nephropathy track together in T1DM (less reliably in T2DM).

Step 3 management: Diabetic nephropathy is a clinical diagnosis; biopsy is reserved for atypical features. Screening (not symptoms) drives detection — making annual surveillance the cornerstone outpatient task.

Definition: Chronic kidney disease attributable to diabetes mellitus, characterized by persistent albuminuria, declining eGFR, and/or biopsy-proven diabetic glomerulosclerosis (Kimmelstiel–Wilson nodules, mesangial expansion, GBM thickening).

Epidemiology:

Natural history (classic T1DM model):

When to suspect in clinic:

Atypical features that argue AGAINST diabetic nephropathy:

Presentation Patterns and Key History

— Most patients are detected on routine annual screening with urine albumin-to-creatinine ratio (UACR) and eGFR — not via symptoms.

— Step 3 vignettes often open with "routine follow-up in clinic" rather than acute illness.

— Edema (lower extremity, periorbital) from nephrotic-range proteinuria.

— Fatigue, anorexia, pruritus, nocturia, dyspnea (volume overload) once eGFR <30.

— Uremic symptoms (nausea, asterixis, pericardial rub) at eGFR <15.

— Diabetes duration, A1c trajectory, prior A1c history (DCCT/UKPDS legacy effect).

— BP control history, antihypertensive classes used.

— Other microvascular complications: retinopathy (last dilated eye exam), neuropathy (monofilament, symptoms).

— Macrovascular disease: CAD, stroke, PAD — these often coexist and shift management.

— Medication review: NSAIDs, PPIs, herbal supplements, IV contrast exposures, ACE/ARB use.

— Family history of CKD, polycystic kidney disease, hereditary nephritis.

— Smoking (accelerates albuminuria progression).

— Poor glycemic control (A1c >9%), HTN, obesity, dyslipidemia, smoking, OSA.

— Black or Hispanic ethnicity; family history of diabetic ESKD.

— Gross hematuria, recent strep infection, rash/arthralgias (lupus, vasculitis), monoclonal gammopathy symptoms, hepatitis exposure, NSAID overuse.

Key distinction: In T2DM, albuminuria or reduced eGFR can be present at diagnosis because hyperglycemia predates clinical recognition by years — therefore screening begins at the time of T2DM diagnosis, but is delayed until 5 years after diagnosis in T1DM.

Board pearl: A patient with longstanding T2DM presenting with new pedal edema and a UACR >2000 mg/g — think advancing diabetic nephropathy with nephrotic-range proteinuria; rule out heart failure and venous insufficiency concurrently.

Typical asymptomatic presentation:

Symptomatic late-stage presentation:

Key history elements to elicit:

Risk factor profile that raises pretest probability:

Red-flag history pointing away from diabetic nephropathy:

Physical Exam Findings (and Hemodynamic Assessment)

— Often unremarkable in early disease — emphasizes that exam is insensitive for screening.

— In advanced disease: pallor (anemia of CKD), sallow complexion, uremic frost (rare).

— Hypertension is nearly universal — measure BP correctly (seated, rested, appropriate cuff, both arms initially).

— Orthostatic vitals in patients on diuretics, RAAS blockers, or with autonomic neuropathy.

— Office BP goal per KDIGO 2021: SBP <120 mm Hg using standardized measurement (ACC/AHA aligns; ADA permits <130/80 individualized).

— JVP elevation, lung crackles, S3 gallop → volume overload.

— Pitting edema of lower extremities, sacral edema in bedbound.

— Periorbital edema suggests significant proteinuria.

— Carotid bruits, diminished pedal pulses, abdominal bruit (renal artery stenosis — a key mimic in older T2DM).

— Look for LVH signs (laterally displaced PMI).

— Diabetic dermopathy, acanthosis nigricans, necrobiosis lipoidica.

— Charcot foot, ulcers, calciphylaxis lesions in advanced CKD.

— Document diabetic retinopathy — dot-blot hemorrhages, hard exudates, neovascularization.

— Coexisting retinopathy supports diabetic etiology of nephropathy in T1DM.

— Decreased monofilament sensation, absent ankle reflexes, autonomic features (resting tachycardia, orthostasis).

— Encephalopathy/asterixis suggest uremia in late stage.

Step 3 management: When BP is elevated in clinic, confirm with home BP monitoring or 24-hr ambulatory BP before escalating therapy — "white coat" and masked hypertension are common in diabetic CKD and change drug choices.

CCS pearl: On a CCS case of advancing nephropathy, order fundoscopic exam, peripheral pulses, monofilament testing, and standing/sitting BP — these score points by addressing the full microvascular and macrovascular footprint.

General appearance:

Vital signs and hemodynamics:

Volume status assessment:

Cardiovascular exam:

Skin and extremities:

Eye exam:

Neurologic exam:

Diagnostic Workup — Initial Labs / Imaging / Screening Tests

— Spot urine albumin-to-creatinine ratio (UACR) on a random sample — preferred over 24-hr collection.

— Serum creatinine with eGFR (CKD-EPI 2021 equation, race-free).

— Frequency: annually, starting at T2DM diagnosis or 5 years after T1DM onset.

— Increase to at least twice yearly if UACR ≥30 mg/g or eGFR <60.

— Normal: <30 mg/g.

— Moderately increased (formerly "microalbuminuria"): 30–300 mg/g (A2).

— Severely increased (formerly "macroalbuminuria"): >300 mg/g (A3).

— Confirm with 2 of 3 abnormal samples over 3–6 months before labeling — transient elevations occur with exercise, fever, UTI, hyperglycemia, menstruation, CHF.

— G1 (≥90), G2 (60–89), G3a (45–59), G3b (30–44), G4 (15–29), G5 (<15).

— Combine with albuminuria categories A1/A2/A3 for risk stratification.

— BMP (K+, bicarbonate, anion gap), CBC (anemia), urinalysis with microscopy (look for hematuria, casts), lipid panel, A1c, PTH, phosphorus, calcium, 25-OH vitamin D once eGFR <60.

— Renal ultrasound at first diagnosis of CKD — assess size, echogenicity, obstruction, asymmetry (asymmetric kidneys → suspect renovascular disease).

— Kidneys in diabetic nephropathy are often normal-sized or enlarged even with advanced disease (vs. small/scarred in most CKD).

Board pearl: A patient with diabetes whose kidneys are unexpectedly small or asymmetric on ultrasound — pivot the differential toward renal artery stenosis, chronic pyelonephritis, or congenital pathology, not diabetic nephropathy.

Step 3 management: When a screening UACR comes back at 80 mg/g, don't initiate therapy on a single value — confirm with a repeat in 1–3 months while addressing transient causes (glycemic spike, UTI, recent exercise).

Screening tests (ADA 2024 + KDIGO 2022):

Interpreting UACR:

CKD staging (KDIGO heat map):

Additional initial labs:

Imaging:

Diagnostic Workup — Advanced or Confirmatory Studies

— eGFR <30 (KDIGO referral threshold).

— Rapidly declining eGFR (>5 mL/min/yr or sustained >30% drop).

— Nephrotic-range proteinuria with short DM duration (<5 yr T1DM).

— Active urine sediment: dysmorphic RBCs, RBC casts, cellular casts.

— Absence of retinopathy in T1DM with proteinuria.

— Refractory hypertension, hyperkalemia, or anemia disproportionate to CKD stage.

— Suspicion of alternative diagnosis (paraproteinemia, vasculitis, lupus).

— SPEP/UPEP with immunofixation, serum free light chains (myeloma).

— ANA, anti-dsDNA, complement C3/C4 (lupus).

— ANCA panel (vasculitis), anti-GBM (Goodpasture).

— Hepatitis B/C, HIV serologies (membranous, MPGN).

— Cryoglobulins if hepatitis C positive.

— Not routinely done in classic diabetic nephropathy.

— Pathology: Kimmelstiel–Wilson nodules (pathognomonic), mesangial expansion, GBM thickening, arteriolar hyalinosis (both afferent and efferent — a diabetic hallmark), capsular drops.

— Tervaert classification: Class I–IV (mesangial → diffuse → nodular → advanced sclerotic).

— Renal artery Doppler or MRA if RAS suspected (asymmetric kidneys, flash pulmonary edema, abrupt AKI on ACEi/ARB).

— Cystatin C–based eGFR when creatinine is unreliable (sarcopenia, amputation, extreme body habitus).

Key distinction: Hyalinosis of both afferent and efferent arterioles is characteristic of diabetic nephropathy. Hypertensive nephrosclerosis classically spares the efferent arteriole — a tested histologic discriminator.

Board pearl: A 28-year-old with T1DM × 3 years presents with 6 g/day proteinuria and no retinopathy — order biopsy, not just empiric ACEi; minimal change disease, FSGS, or membranous can masquerade and require different therapy.

Indications for nephrology referral and possible biopsy:

Workup for non-diabetic CKD when atypical features present:

Renal biopsy:

Functional/specialty testing:

Risk Stratification and First-Line Management Logic

— Low risk: G1–G2 + A1 → annual screening only.

— Moderate: G1–G2 A2 or G3a A1 → intervene on BP, glucose, ASCVD risk.

— High: G3a A2, G3b A1, G1–G2 A3 → all above + nephrology referral consideration.

— Very high: G3b A2+, G4–G5 any, A3 with G3a+ → nephrology referral mandatory.

— 1. RAAS blockade (ACEi or ARB) — for albuminuria or HTN.

— 2. SGLT2 inhibitor — for eGFR ≥20 with T2DM and CKD (or with HF/albuminuria).

— 3. Nonsteroidal MRA (finerenone) — for T2DM + albuminuria on max ACEi/ARB with eGFR ≥25 and K+ ≤4.8.

— 4. GLP-1 receptor agonist — for additional glycemic and cardiorenal benefit, especially with ASCVD or obesity.

— A1c individualized: typically <7%, relaxed to 7–8% in advanced CKD, frailty, hypoglycemia risk.

— BP <130/80 (ADA) or <120 SBP standardized (KDIGO).

— LDL: high-intensity statin for any CKD with diabetes; ezetimibe/PCSK9 if not at goal.

— Dietary sodium <2 g/day, protein 0.6–0.8 g/kg/day in non-dialysis CKD (avoid <0.6 → malnutrition).

— Smoking cessation, weight reduction, aerobic activity ≥150 min/week.

— Aspirin for secondary prevention only (primary prevention individualized in DM + CKD).

— Address OSA, depression, vaccination (influenza, pneumococcal, hepatitis B prior to dialysis).

Step 3 management: In a T2DM patient with eGFR 50 and UACR 250 mg/g not yet on RAAS blockade, the single highest-yield order is to start an ACEi or ARB and titrate to max tolerated dose — even if BP is at goal, because albuminuria reduction itself is renoprotective.

Board pearl: The "4-pillar" stack (ACEi/ARB + SGLT2i + finerenone + GLP-1 RA) has additive cardiorenal benefit — Step 3 tests sequence and eligibility, not exclusion.

KDIGO heat map risk categories (combine G and A stages):

Pillars of diabetic nephropathy management (think "4 pillars"):

Concurrent lifestyle and metabolic targets:

ASCVD risk modification:

Pharmacotherapy — First-Line Drug Regimen

— Indications: HTN in any diabetic, OR any albuminuria (UACR ≥30) regardless of BP, OR eGFR <60 with diabetes.

— Examples: lisinopril 10–40 mg daily, losartan 50–100 mg daily, telmisartan 40–80 mg daily.

— Titrate to maximum tolerated dose — albuminuria reduction is dose-dependent.

— Do NOT combine ACEi + ARB (ONTARGET: increased AKI, hyperkalemia, no benefit).

— Monitor BMP at baseline, 1–2 weeks after initiation/titration, then periodically.

— Acceptable: SCr rise up to 30% within 2–4 weeks — reflects intraglomerular pressure reduction, do not discontinue.

— Stop or pause if: K+ >5.5 refractory to mitigation, SCr rise >30%, symptomatic hypotension, AKI, pregnancy.

— Empagliflozin, dapagliflozin, canagliflozin.

— Start if eGFR ≥20 with T2DM + CKD (albuminuria or reduced eGFR), regardless of A1c.

— Continue until dialysis or transplant per current labeling.

— Benefits: ~30% reduction in CKD progression, HF hospitalization, CV death.

— Risks: euglycemic DKA (hold for surgery/illness), genital mycotic infections, volume depletion, rare Fournier gangrene.

— Expect a small initial eGFR dip (3–5 mL/min) that stabilizes — not a reason to stop.

— For T2DM + albuminuria on max ACEi/ARB; eGFR ≥25; K+ ≤4.8.

— Dose: 10 mg daily if eGFR 25–60; 20 mg if eGFR ≥60. Recheck K+ in 4 weeks.

— Less gynecomastia than spironolactone; still monitor potassium.

— Semaglutide, dulaglutide, liraglutide — add for glycemic control, weight loss, ASCVD benefit; FLOW trial showed renal benefit with semaglutide.

Board pearl: A 30% rise in creatinine after ACEi initiation is expected and protective — do not stop the drug; recheck in 2 weeks and confirm stabilization.

Step 3 management: Sequence on CCS — ACEi/ARB first, then SGLT2i, then finerenone if albuminuria persists, then GLP-1 RA for glycemic/CV layering.

ACE inhibitors and ARBs (foundation therapy):

SGLT2 inhibitors:

Nonsteroidal MRA — finerenone:

GLP-1 receptor agonists:

Expanded Pharmacology and Glycemic Agent Selection

— Metformin: Safe down to eGFR 30; do not initiate below 45; discontinue at eGFR <30. Hold for contrast, surgery, acute illness.

— SGLT2 inhibitors: Preferred for CKD with or without T2DM; initiate at eGFR ≥20.

— GLP-1 RAs: No dose adjustment for kidney function for most agents; preferred when SGLT2i contraindicated or for additional weight/ASCVD benefit.

— DPP-4 inhibitors: Renally dose-adjust (sitagliptin, saxagliptin); linagliptin needs no adjustment. Saxagliptin → ↑HF hospitalization (avoid).

— Sulfonylureas: Avoid glyburide (long-acting metabolites, hypoglycemia); use glipizide if needed.

— TZDs: Avoid in CKD with HF/volume overload (fluid retention).

— Insulin: Reduce dose as eGFR falls — clearance drops, hypoglycemia risk rises (especially eGFR <30).

— Thiazide-like (chlorthalidone, indapamide) — effective even at eGFR 30–45 (CLICK trial).

— Loop diuretic (furosemide, torsemide) when eGFR <30 or volume overload.

— Dihydropyridine CCB (amlodipine) — good add-on; no albuminuria-specific benefit but BP control.

— Avoid non-DHP CCBs combined with beta-blockers (bradycardia).

— High-intensity statin (atorvastatin 40–80, rosuvastatin 20–40) for any DM + CKD age 40–75.

— Add ezetimibe if LDL >70 on max statin; PCSK9 inhibitor for very high-risk ASCVD.

— Statins not initiated in dialysis patients (no mortality benefit per 4D, AURORA), but continued if already on them.

— Low-K diet counseling, loop or thiazide diuretic, correction of acidosis (bicarb to keep HCO3 >22), potassium binders (patiromer, sodium zirconium cyclosilicate) — enable maximal RAAS dosing.

CCS pearl: When potassium rises to 5.6 on an ACEi, do not stop the drug first — order dietary counseling, add/uptitrate diuretic, consider patiromer, then recheck before discontinuing RAAS therapy.

Glycemic agent choice in diabetic CKD (ADA 2024):

Antihypertensive layering beyond RAAS:

Lipid management:

Potassium management to allow RAAS continuation:

Special Populations — Elderly and Renal/Hepatic Impairment

— eGFR overestimates function in sarcopenic elderly — use cystatin C if creatinine appears discordant with clinical picture.

— Hypoglycemia risk rises sharply >65; relax A1c target to 7.5–8.0% in frailty, life expectancy <10 years, or significant comorbidity.

— Avoid glyburide, long-acting sulfonylureas; favor DPP-4i (linagliptin), GLP-1 RA, or basal insulin with careful titration.

— Orthostatic hypotension limits aggressive BP targets — measure standing BP, individualize goal (often <140/90 in frail elderly per ADA).

— Review NSAIDs, OTC analgesics, herbal supplements, PPIs.

— Deprescribe nephrotoxins; check for renally-dosed antibiotics, gabapentin (accumulates in CKD → sedation, myoclonus), digoxin.

— Pioglitazone contraindicated in active liver disease; check LFTs before starting.

— Statins generally safe in stable chronic liver disease (NAFLD common in T2DM); avoid in decompensated cirrhosis.

— Metformin: avoid in advanced cirrhosis with hepatic encephalopathy or unstable liver function due to lactic acidosis risk.

— Continue SGLT2i down to dialysis per current labeling.

— ACEi/ARB: continue unless symptomatic hypotension, refractory hyperkalemia, or AKI; STOP-ACEi trial showed no benefit but no harm to discontinuation in advanced CKD — individualize.

— Treat CKD-MBD: bind phosphate (non-calcium binders preferred), check PTH, activated vitamin D analogs as needed.

— Anemia: iron repletion, ESA when Hb <10 (target 10–11.5, not above).

— Acidosis: oral bicarbonate to keep HCO3 ≥22 (slows progression).

— Iodinated contrast: hydrate (isotonic saline) for eGFR <30; risk of CIN is lower than historically taught but still present.

— Gadolinium: avoid group I agents in eGFR <30 due to NSF; group II macrocyclic agents are safer.

Board pearl: In a frail 82-year-old with diabetic CKD, an A1c of 6.2% on insulin is too low — it predicts hypoglycemia and falls. Step 3 expects you to deintensify, not congratulate.

Geriatric considerations:

Polypharmacy minimization:

Hepatic impairment:

Advanced CKD (G4–G5, not yet on dialysis):

Contrast exposure:

Special Populations — Pregnancy, Pediatrics, and Transplant

— Preconception counseling: optimize A1c to <6.5%, BP <135/85, switch ACEi/ARB off before conception (teratogenic — renal dysgenesis, oligohydramnios, fetal hypotension).

— Acceptable antihypertensives: labetalol, nifedipine, methyldopa, hydralazine.

— Stop SGLT2i, GLP-1 RA, statins, finerenone before conception.

— Glycemic control: insulin is gold standard; metformin can be continued but often supplemented with insulin.

— Monitor for superimposed preeclampsia — baseline proteinuria complicates the diagnosis; rely on BP trajectory, LFTs, platelets, uric acid.

— Higher risk of preterm delivery, IUGR, perinatal mortality.

— Screen annually starting at age 11 with diabetes duration ≥5 years.

— Transient pubertal albuminuria common — confirm persistence.

— ACEi initiation in adolescents with confirmed persistent albuminuria; counsel sexually active females on teratogenicity and contraception.

— Refer for transplant evaluation when eGFR <20 — preemptive transplant has superior outcomes vs. dialysis.

— Simultaneous pancreas-kidney (SPK) transplant for T1DM with ESKD provides insulin independence and renal allograft.

— Post-transplant diabetes (NODAT) risk with tacrolimus, steroids.

— Plan vascular access (AV fistula) when eGFR ~15–20 to allow maturation.

— Avoid PICC lines and subclavian central access in CKD patients (preserve veins).

— Educate on modality choice: HD vs. peritoneal dialysis (PD favored for residual function, lifestyle, fewer hemodynamic swings — but peritonitis risk).

Step 3 management: A 28-year-old T1DM woman on lisinopril plans pregnancy in 6 months — switch to labetalol or nifedipine now, counsel on glycemic optimization, refer to MFM and endocrinology. Do not wait for a positive pregnancy test.

Board pearl: Refer for transplant at eGFR <20, not at dialysis initiation — the eligibility clock for the deceased donor list starts at eGFR 20 or dialysis start, whichever comes first.

Pregnancy in diabetic nephropathy:

Pediatric/adolescent T1DM:

Kidney transplant considerations:

Dialysis transition:

Complications and Adverse Outcomes

— Diabetic CKD has cardiovascular mortality > progression to ESKD risk — most patients die before reaching dialysis.

— Accelerated atherosclerosis, MI, stroke, heart failure (especially HFpEF), sudden cardiac death.

— Vascular calcification (medial Mönckeberg sclerosis) — non-compressible ankle vessels, falsely elevated ABI.

— Fluid retention from impaired sodium excretion plus insulin-driven sodium retention.

— Manage with sodium restriction, loop diuretics (often high-dose in CKD), SGLT2i, MRA.

— Especially with RAAS inhibitors, NSAIDs, trimethoprim, heparin, beta-blockers, low aldosterone state.

— Manage with dietary K restriction, loop/thiazide diuretic, bicarbonate for acidosis, patiromer/SZC.

— Loss of nephron mass → reduced acid excretion; HCO3 <22 accelerates CKD progression and muscle wasting.

— Oral sodium bicarbonate 650 mg BID–TID to target HCO3 ≥22.

— Erythropoietin deficiency; usually appears at eGFR <30 (later than in non-diabetic CKD).

— Workup: iron studies, B12, folate, reticulocyte count. Replete iron first (ferritin >100, TSAT >20%), then ESA if Hb <10.

— ↑Phosphate, ↑PTH, ↓1,25-vitamin D, vascular calcification.

— Phosphate binders (non-calcium preferred when calcification present), calcitriol or analogs, cinacalcet for refractory secondary hyperparathyroidism.

— Recurrent UTIs (glucosuria, autonomic bladder dysfunction).

— Papillary necrosis (gross hematuria, flank pain).

— Type 4 RTA (hyporeninemic hypoaldosteronism) — non-anion-gap acidosis with hyperkalemia, classic in DM.

— Increased infection risk, poor wound healing, contrast-induced AKI.

— Sexual dysfunction (autonomic + vascular + hormonal).

Board pearl: A diabetic patient with persistent non-anion-gap metabolic acidosis and hyperkalemia at eGFR 50 — think type 4 RTA (hyporeninemic hypoaldosteronism). Treat with low-K diet, loop diuretic, and fludrocortisone only if symptomatic.

Cardiovascular complications (dominant cause of mortality):

Volume overload and heart failure:

Hyperkalemia:

Metabolic acidosis:

Anemia of CKD:

CKD-mineral bone disorder (CKD-MBD):

Other complications:

When to Escalate Care — Consult, ICU, or Inpatient Triage

— eGFR <30 (mandatory per KDIGO).

— UACR >300 mg/g persistent.

— Rapidly progressive CKD (eGFR loss >5 mL/min/yr).

— Refractory hypertension (>3 drugs including diuretic at max doses).

— Refractory hyperkalemia despite optimization.

— Uncertain etiology of CKD; suspected non-diabetic kidney disease.

— Need for biopsy, dialysis planning, transplant referral.

— CKD-MBD requiring activated vitamin D or binders.

— Severe hyperkalemia (K+ >6.5 or ECG changes — peaked T waves, widened QRS, sine wave).

— Volume overload with hypoxia or refractory CHF.

— Symptomatic uremia (encephalopathy, pericarditis, bleeding diathesis).

— AKI superimposed on CKD with eGFR halving or oligoanuria.

— Severe metabolic acidosis (pH <7.2) unresponsive to oral therapy.

— Acute indications for urgent dialysis: AEIOU — Acidosis, Electrolytes (K+), Ingestions, Overload, Uremia.

— Hyperkalemic cardiac arrhythmia.

— Pulmonary edema requiring BiPAP/intubation.

— Hemodynamic instability requiring vasopressors.

— Uremic pericardial tamponade.

— Refer to vascular surgery for AV fistula when eGFR projected to reach 15–20 within 6–12 months.

— Avoid subclavian lines, PICCs — preserve cephalic and basilic veins.

— Endocrinology for complex glycemic regimens.

— Cardiology for ASCVD risk and HF management.

— Dietitian for renal-friendly diabetic diet.

— Social work, transplant coordinator, dialysis educator in CKD G4+.

CCS pearl: On a CCS case presenting with K+ 7.0 and peaked T waves, the first three orders are: IV calcium gluconate (membrane stabilization), insulin + D50 (intracellular shift), and continuous cardiac monitoring — then loop diuretic, kayexalate/patiromer, and dialysis consult if refractory.

Step 3 management: Document the specific trigger for referral (numeric eGFR, UACR, BP) in your assessment — Step 3 vignettes test the threshold, not the gestalt.

Indications for nephrology referral (outpatient):

Indications for inpatient admission:

ICU triage:

Vascular access planning (transition-of-care priority):

Multidisciplinary involvement:

Key Differentials — Same-Category (Glomerular/Renal) Causes

— Slowly progressive CKD with mild proteinuria (usually <1 g/day), often in Black patients with longstanding HTN.

— Small echogenic kidneys; histology shows arteriolar nephrosclerosis sparing efferent arteriole.

— Often coexists with diabetic nephropathy; treatment overlaps (BP control, RAAS).

— Nephrotic syndrome in adults; check PLA2R antibody.

— Consider in T2DM patient with sudden nephrotic-range proteinuria, especially without retinopathy.

— Secondary causes: hepatitis B, lupus, malignancy, NSAIDs.

— Obesity-related FSGS common in T2DM; also HIV, heroin, APOL1 variants in Black patients.

— Biopsy needed to distinguish from diabetic glomerulosclerosis.

— Abrupt-onset nephrotic syndrome; steroid-responsive.

— Can occur in any age; consider in T1DM with proteinuria <5 years from diagnosis.

— Hematuria (often gross, synpharyngitic) with proteinuria; mesangial IgA deposits.

— Active sediment with RBC casts argues for IgA over diabetic disease.

— Hepatitis C, cryoglobulinemia, monoclonal gammopathy.

— Low complements (C3, C4); requires biopsy.

— Older diabetic with HTN, asymmetric kidneys, flash pulmonary edema, AKI after ACEi initiation >30%.

— Renal Doppler or MRA confirms; revascularize only for refractory HTN/HF (CORAL trial showed limited benefit).

— Older diabetic post-catheterization; livedo reticularis, blue toes, eosinophilia, eosinophiluria, hypocomplementemia.

Key distinction: Diabetic nephropathy → bland sediment, gradual proteinuria, normal-to-large kidneys, retinopathy correlated. Active sediment (RBC casts, dysmorphic RBCs) or rapid progression → alternative glomerular disease, biopsy indicated.

Board pearl: AKI within 1 week of starting ACEi with SCr rise >30% → suspect bilateral renal artery stenosis (or unilateral in a solitary kidney). Order renal Doppler.

Hypertensive nephrosclerosis:

Membranous nephropathy:

Focal segmental glomerulosclerosis (FSGS):

Minimal change disease:

IgA nephropathy:

Membranoproliferative glomerulonephritis (MPGN):

Renal artery stenosis (ischemic nephropathy):

Cholesterol embolization:

Key Differentials — Other-Category Causes of Proteinuria/CKD

— Older patient with anemia, bone pain, hypercalcemia, AKI, foamy urine.

— UACR may be low despite heavy proteinuria (cast nephropathy proteins not detected by albumin-specific tests) — order urine protein-to-creatinine ratio (UPCR) if discordance suspected, plus SPEP/UPEP and serum free light chains.

— Nephrotic-range proteinuria, macroglossia (AL), peripheral neuropathy, hepatosplenomegaly, low-voltage ECG with thick LV walls.

— Congo red stain, apple-green birefringence.

— Younger woman, malar rash, arthritis, cytopenias; positive ANA, anti-dsDNA, low C3/C4.

— Class III/IV need biopsy and immunosuppression.

— Pulmonary-renal syndrome, hemoptysis, sinusitis, RBC casts, rapidly progressive GN.

— c-ANCA/PR3 or p-ANCA/MPO positive.

— Hemoptysis + RPGN in young man.

— 1–3 weeks after strep pharyngitis/impetigo, hematuria, hypertension, low C3.

— HBV → membranous; HCV → MPGN with cryoglobulinemia.

— Collapsing FSGS, heavy proteinuria, rapid progression; APOL1-associated.

— Analgesic nephropathy (NSAIDs), lithium, lead, Chinese herb, sarcoidosis.

— Sterile pyuria, WBC casts, modest proteinuria (<2 g), often with Fanconi features.

— BPH, neurogenic bladder (common in long-standing diabetes with autonomic neuropathy), bilateral hydronephrosis on US.

— Always rule out with renal US and post-void residual in new CKD.

Key distinction: A diabetic patient with anemia disproportionate to CKD stage, hypercalcemia, and unexplained back pain — work up myeloma before attributing CKD to diabetes; SPEP, UPEP with immunofixation, free light chains, skeletal survey or PET-CT.

Board pearl: Always check post-void residual in a diabetic with new or worsening CKD — neurogenic bladder from autonomic neuropathy causes silent obstructive uropathy.

Multiple myeloma / monoclonal gammopathy of renal significance (MGRS):

Amyloidosis (AL or AA):

Lupus nephritis:

ANCA-associated vasculitis (GPA, MPA, EGPA):

Anti-GBM disease (Goodpasture):

Post-infectious GN:

Hepatitis B/C–related nephropathy:

HIV-associated nephropathy (HIVAN):

Chronic interstitial nephritis:

Obstructive uropathy:

Secondary Prevention / Discharge Medications / Long-Term Plan

— ACEi or ARB at maximum tolerated dose.

— SGLT2 inhibitor (empagliflozin, dapagliflozin) if eGFR ≥20.

— Finerenone if T2DM, albuminuria persists on max RAAS, K+ ≤4.8, eGFR ≥25.

— GLP-1 RA for additional glycemic, weight, ASCVD, and renal benefit.

— High-intensity statin for ASCVD primary prevention in DM + CKD age 40–75.

— Antiplatelet (aspirin 81 mg) only for established ASCVD (secondary prevention).

— Individualized A1c target (typically 7%, relaxed in advanced CKD/frailty).

— Continuous glucose monitor consideration to detect hypoglycemia in CKD (decreased gluconeogenesis, insulin clearance).

— Avoid glyburide; reduce insulin doses as eGFR falls.

— Home BP monitoring with validated cuff, twice daily morning/evening.

— Target <130/80 (ADA) or standardized SBP <120 (KDIGO).

— Add thiazide-like diuretic (chlorthalidone, indapamide) early; loop diuretic when eGFR <30.

— DASH-style diet adapted for CKD (lower K with eGFR <45).

— Sodium <2 g/day, protein 0.6–0.8 g/kg/day in non-dialysis CKD.

— Smoking cessation, alcohol moderation, weight loss 5–10% if BMI ≥30.

— Aerobic activity ≥150 min/week + 2 sessions resistance training.

— Annual influenza, COVID-19 boosters per CDC.

— Pneumococcal (PCV20 or PCV15 + PPSV23 sequence).

— Hepatitis B vaccination before dialysis (higher-dose series for CKD: 40 mcg × 4 doses).

— RSV vaccine if age ≥60.

— Zoster (Shingrix) if ≥50.

— BMP, CBC, UACR, eGFR, PTH/phosphorus/calcium/25-OH D in G4+.

Step 3 management: Discharge a diabetic with new CKD on a bundle: ACEi/ARB + SGLT2i + statin + glycemic optimization + sodium counseling + nephrology referral if eGFR <30 — leaving any pillar off is the wrong answer.

Core long-term medication regimen for diabetic nephropathy:

Glycemic plan:

Blood pressure plan:

Lifestyle and behavioral:

Vaccinations:

CKD-specific monitoring panel (at follow-up):

Follow-Up, Monitoring Parameters, and Counseling Cadence

— G1–G2 A1 (low risk): annual UACR, eGFR, BP, A1c.

— G1–G2 A2 or G3a A1: every 6 months.

— G3a A2, G3b A1, G1–G2 A3: every 4 months.

— G3b A2+, G4 any: every 3 months; nephrology co-management.

— G5 or pre-dialysis: monthly to biweekly; dialysis education.

— Check BMP at 1–2 weeks, then 4 weeks, then quarterly.

— Acceptable creatinine rise: up to 30% above baseline.

— Acceptable potassium: <5.5 (mitigate above this).

— Expected initial eGFR dip of 3–5 mL/min — recheck at 2–4 weeks.

— Counsel sick-day rules: hold during dehydration, surgery, severe illness (euglycemic DKA risk).

— Genital hygiene counseling.

— Check K+ at 4 weeks, then quarterly.

— Dose adjust based on K+ trajectory.

— A1c every 3 months until at target, then every 6 months.

— CGM data review at each visit if applicable.

— PTH, phosphate, calcium every 3–6 months in G4; more frequent in G5.

— 25-OH vitamin D annually.

— Dilated eye exam (diabetic retinopathy).

— Comprehensive foot exam, monofilament.

— Lipid panel.

— Depression screening (PHQ-2/9), cognitive screen in elderly.

— Sick-day rules: hold ACEi/ARB, SGLT2i, metformin, NSAIDs during acute volume depletion or febrile illness.

— Nephrotoxin avoidance: NSAIDs, IV contrast risk discussion, herbal supplements.

— Advance care planning early in G4+ — modality selection, conservative care option.

CCS pearl: Always schedule the follow-up visit with explicit interval ("return in 2 weeks for BMP after lisinopril titration") — Step 3 CCS scores the cadence, not just the prescription.

Board pearl: Sick-day rules are tested — patient with N/V/diarrhea on ACEi + SGLT2i + metformin should hold all three until rehydrated, to prevent AKI, euglycemic DKA, and lactic acidosis.

Outpatient monitoring schedule by KDIGO stage:

After starting/titrating ACEi, ARB, MRA, or diuretic:

After starting SGLT2i:

After starting finerenone:

Diabetes monitoring:

CKD-MBD monitoring (G3b+):

Other annual screening:

Counseling elements:

Ethical, Legal, and Patient Safety Considerations

— Modality selection at ESKD transition: hemodialysis vs. peritoneal dialysis vs. transplant vs. conservative (non-dialytic) management.

— In elderly patients (>75) with multiple comorbidities and frailty, dialysis may not extend life or improve quality — discuss conservative care explicitly. Failing to offer it is an ethical lapse.

— Document goals-of-care conversations; involve palliative care early in CKD G4–G5.

— Hospital discharge with new diuretic + ACEi increases AKI/hyperkalemia risk — schedule BMP within 1 week.

— Hold-and-restart medication errors: sick-day instructions often missed at discharge.

— Medication reconciliation: NSAIDs prescribed for orthopedic pain at discharge can precipitate AKI.

— Communicating eGFR-based dose adjustments to pharmacies and primary care.

— Black, Hispanic, and Native American patients have higher diabetic ESKD rates and lower preemptive transplant rates — proactive transplant referral is a justice imperative.

— The 2021 CKD-EPI race-free eGFR equation removed race coefficient; ensure your lab uses updated equation.

— Insurance navigation: Medicare covers ESKD regardless of age after dialysis initiation or transplant — counsel patients.

— "Sick day" wallet card listing meds to hold.

— Contrast/imaging "stop list" alert in EHR for ACEi/ARB, SGLT2i, metformin.

— Vascular access preservation: signage to avoid blood draws and PICCs in the non-dominant arm of CKD G4+ patients.

— Driving safety with recurrent hypoglycemia — many states require reporting impaired drivers; counsel and document.

— Workplace accommodations for dialysis schedules (ADA protections).

— Uremic encephalopathy can impair decisional capacity — assess before major decisions; use surrogate decision-makers per state hierarchy.

— Discuss code status, dialysis withdrawal preferences, POLST/MOLST forms.

Step 3 management: A 78-year-old with dementia, diabetic ESKD, and frailty is offered dialysis — the correct first step is a structured goals-of-care discussion offering conservative kidney management alongside dialysis, not automatic AV fistula placement.

Informed consent and shared decision-making:

Transition-of-care risks (Step 3 favorite):

Health equity and access:

Patient safety bundles:

Mandatory reporting and legal considerations:

Capacity and advance directives:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When a question gives you a diabetic with eGFR 55, UACR 220, BP 128/78, A1c 7.2%, already on lisinopril — the next best step is to add an SGLT2 inhibitor, not uptitrate lisinopril or change A1c targets.

Pathognomonic histology: Kimmelstiel–Wilson nodules (nodular glomerulosclerosis).

Earliest functional change: Glomerular hyperfiltration (↑GFR before any albuminuria).

Earliest detectable lab abnormality: Moderately increased albuminuria (UACR 30–300).

eGFR equation in use (2024): CKD-EPI 2021, race-free.

Screening cadence: Annual UACR + eGFR; start at T2DM diagnosis, 5 yr post T1DM onset.

Confirmation: 2 of 3 abnormal UACR samples over 3–6 months.

First-line drug: ACEi or ARB — never both together.

Second-line drug (game changer): SGLT2 inhibitor down to eGFR 20.

Add-on for residual albuminuria: Finerenone (nonsteroidal MRA).

Acceptable creatinine bump after ACEi: Up to 30%.

Hold contrast/SGLT2i/metformin/ACEi for: Acute illness, dehydration, surgery (sick-day rules).

Kidney size in diabetic nephropathy: Normal or enlarged (vs. small in most CKDs).

Arteriolar hyalinosis: Both afferent AND efferent (diabetic hallmark vs. afferent-only in HTN).

Retinopathy correlation: Strong in T1DM, weaker in T2DM.

Atypical features → biopsy: Hematuria, RBC casts, rapid decline, no retinopathy in T1DM, nephrotic onset <5 yr T1DM.

Type 4 RTA: Hyporeninemic hypoaldosteronism — classic in DM with non-anion-gap acidosis + hyperkalemia.

DKA risk on SGLT2i: Euglycemic DKA — glucose may be near-normal.

Hepatitis B vaccine: Higher-dose series (40 mcg × 4) for CKD before dialysis.

AV fistula timing: Refer at eGFR 15–20 to allow maturation (6+ weeks).

Transplant referral: eGFR <20.

Pregnancy: Stop ACEi/ARB, SGLT2i, GLP-1 RA, statins, finerenone preconception.

Cardiovascular mortality > ESKD risk in most diabetic CKD patients.

Cause of ESKD #1 in US: Diabetic kidney disease.

Board Question Stem Patterns

— 55 y/o T2DM × 8 yr, BP 132/82, A1c 7.4%, UACR 85 mg/g (confirmed on repeat), eGFR 78. Not on RAAS.

— Answer: Start ACEi or ARB regardless of BP.

— Already on max losartan; UACR still 350, eGFR 52, K+ 4.4.

— Answer: Add SGLT2 inhibitor; if albuminuria persists later, add finerenone.

— Distractor: stop the drug.

— Answer: Continue ACEi, recheck in 2 weeks; <30% rise is expected and protective.

— T1DM × 4 yr, no retinopathy, 5 g/day proteinuria, RBC casts.

— Answer: Refer to nephrology for biopsy — consider alternative glomerular disease.

— Older diabetic, BP 168/92, started lisinopril → SCr 1.4 → 2.6 in 5 days.

— Answer: Stop ACEi, order renal Doppler — bilateral RAS suspected.

— T2DM on metformin + empagliflozin + lisinopril presents with gastroenteritis and AKI.

— Answer: Hold all three; resume after rehydration.

— 30 y/o T1DM nephropathy on lisinopril, plans conception.

— Answer: Switch to labetalol or nifedipine preconception.

— K+ 5.4 on max losartan; UACR 600.

— Answer: Add patiromer or SZC, optimize diet/diuretic — don't stop the ARB.

— 82 y/o on insulin, A1c 6.1%, two recent hypoglycemic episodes.

— Answer: Deintensify; target A1c 7.5–8.0%.

— eGFR 18, declining; on RAAS, SGLT2i, statin.

— Answer: Refer to vascular surgery for AV fistula AND to transplant evaluation.

Step 3 management: The most common Step 3 trap is stopping ACEi/ARB for a modest creatinine bump or borderline hyperkalemia — the correct answer is almost always to mitigate and continue, because RAAS withdrawal accelerates progression.

Board pearl: When stems give you a "next best step" with multiple correct-sounding interventions, sequence by mortality and renal benefit: BP/RAAS → SGLT2i → glycemic optimization → lipids → finerenone → GLP-1 → vaccinations.

Pattern 1 — "Annual visit, new microalbuminuria":

Pattern 2 — "Established CKD, what's the next pillar":

Pattern 3 — "Creatinine rose 25% after ACEi started":

Pattern 4 — "Atypical features prompting biopsy":

Pattern 5 — "Bilateral RAS unmasked":

Pattern 6 — "Sick-day rules":

Pattern 7 — "Pregnancy planning":

Pattern 8 — "Hyperkalemia management to preserve RAAS":

Pattern 9 — "Frail elderly with low A1c":

Pattern 10 — "Vascular access timing":

One-Line Recap

Diabetic nephropathy management is annual UACR + eGFR screening with maximally tolerated ACEi/ARB plus an SGLT2 inhibitor as the foundational duo, layered with finerenone and GLP-1 RA for residual albuminuria and cardiometabolic risk, alongside individualized BP and glycemic targets, sick-day medication holds, and timely nephrology, vascular access, and transplant referrals to prevent or delay ESKD.

Board pearl: The single highest-yield Step 3 reflex is: "Diabetic with albuminuria? Start ACEi/ARB, add SGLT2i, schedule BMP in 2 weeks, and confirm follow-up nephrology referral if eGFR <30 or UACR >300."

Step 3 management: Think in pillars, not single drugs — and always reconcile sick-day rules, contrast holds, and vaccination status at every transition of care to prevent preventable AKI and accelerated progression to ESKD.

Screening: Annual UACR + eGFR — start at T2DM diagnosis, 5 years post T1DM onset; confirm abnormal results with 2 of 3 samples over 3–6 months. Atypical features (RBC casts, rapid decline, no retinopathy in T1DM, early nephrotic syndrome) prompt biopsy.

First-line therapy: Max-tolerated ACEi or ARB (never combined) for any albuminuria or HTN; tolerate up to 30% creatinine rise; manage hyperkalemia with diet, diuretics, and binders rather than discontinuation.

Cardiorenal stacking: SGLT2 inhibitor down to eGFR 20 → finerenone if albuminuria persists and K+ ≤4.8 → GLP-1 RA for glycemic, weight, and ASCVD benefit → high-intensity statin → BP <130/80 (ADA) or standardized SBP <120 (KDIGO).

Transition planning: Nephrology referral at eGFR <30, AV fistula at eGFR 15–20, transplant evaluation at eGFR <20; in frail elderly, offer conservative kidney management as an equally valid goals-of-care path.